Pharmather Announces Exclusive License Agreement with the University of Arizona for the Commercialization of Ketamine in the Treatment of Parkinson’s Disease

Oct 15, 2020

TORONTO, Oct. 15, 2020 – Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is...

Pharmather Engages Clarus Securities As Capital Markets Advisor

Oct 13, 2020

TORONTO, Oct. 13, 2020 – Pharmather Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“Pharmather” or the “Company”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is...

DigiMax Completes Acquisition of DataNavee

Sep 18, 2020

TORONTO, ON /  September 18, 2020 / DigiCrypts Blockchain Solutions Inc. o/a DIGIMAX GLOBAL SOLUTIONS (the “Company” or “DigiMax”) (CSE:DIGI) is pleased to announce that it has completed the acquisition of DataNavee Corporation. Pursuant to the...

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

Sep 16, 2020

TORONTO, Sept. 16, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the...

Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

Sep 2, 2020

TORONTO, Sept. 02, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the...